Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients
Authors:
- Joerg WendlerJWJoerg Wendler
- Gerd R BurmesterGBGerd R Burmester
- Helmut SörensenHSHelmut Sörensen
- Andreas KrauseAKAndreas Krause
- Constanze RichterCRConstanze Richter
- Hans-Peter TonyHTHans-Peter Tony
- Andrea Rubbert-RothARAndrea Rubbert-Roth
- Peter Bartz-BazzanellaPBPeter Bartz-Bazzanella
- Siegfried WassenbergSWSiegfried Wassenberg
- Iris Haug-RostIHIris Haug-Rost
- Thomas DörnerTDThomas Dörner
Open Access
- 26 March 2014
- journal article
- clinical trial
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (2) , R80
Abstract
Introduction: The aim of this study was to evaluate the safety and efficacy of rituximab (RTX) in a large cohort of patients with rheumatoid arthritis in routine care, and to monitor changes in daily practice since the introduction of RTX therapy. Methods: This was a multicentre, prospective, non-interventional study conducted under routine practice conditions in Germany. Efficacy was evaluated using Disease Activity Score in 28 joints (DAS28) and Health Assessment Questionnaire-Disability Index (HAQ-DI). Safety was assessed by recording adverse drug reactions (ADRs). Physician and patient global efficacy and tolerability assessments were also evaluated. Results: Overall, 2,484 patients (76.7% female, mean age 56.4 years, mean disease duration 11.7 years) received RTX treatment (22.7% monotherapy). The total observation period was approximately six-years (median follow-up 14.7 months). RTX treatment led to improvements in DAS28 and HAQ-DI that were sustained over multiple courses. DAS28 improvements positively correlated with higher rheumatoid factor levels up to 50 IU/ml. Response and tolerability were rated good/very good by the majority of physicians and patients. Mean treatment intervals were 10.5 and 6.8 months for the first and last 400 enrolled patients, respectively. Infections were the most frequently reported ADRs (9.1%; 11.39/100 patient-years); approximately 1% of patients per course discontinued therapy due to ADRs. Conclusions: Prolonged RTX treatment in routine care is associated with good efficacy and tolerability, as measured by conventional parameters and by physicians’ and patients’ global assessments. Rheumatoid factor status served as a distinct and quantitative biomarker of RTX responsiveness. With growing experience, physicians repeated treatments earlier in patients with less severe disease activity.Keywords
This publication has 17 references indexed in Scilit:
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsAnnals of the Rheumatic Diseases, 2013
- Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX StudyThe Journal of Rheumatology, 2012
- Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesAnnals of the Rheumatic Diseases, 2011
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategiesArthritis Research & Therapy, 2010
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 2010
- Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysisArthritis & Rheumatism, 2007
- Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trialsArthritis & Rheumatism, 2006
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Robust Locally Weighted Regression and Smoothing ScatterplotsJournal of the American Statistical Association, 1979